Skip to content
Menu

Calidi Biotherapeutics Reports Two Posters At European Society For Medical Oncology From Its RedTail Platform

Benzinga Newsdesk 3 weeks ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that it presented two posters

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that it presented two posters at the European Society for Medical Oncology (ESMO) Congress 2026 last week in Madrid. The presentations showcased new data from the Company’s RedTail platform, a systemically delivered virotherapy platform engineered to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly within tumors.

Read at benzinga.com

← All stock news